In this study, we have identified the NCoR1/RARα complex as a major transcriptional regulator of CMA activity in NSCLC and demonstrated its therapeutic value as a novel druggable target for pharmacological inhibition of CMA. This evidence concerns the gene RARA and non-small cell lung carcinoma.